Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-SLE 1: Phase 3 ianalumab in systemic lupus erythematosus
jRCT2061220094Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Novartis. Primary endpoint: Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at Week 60. Started Jun 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2061220094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220094.